Full Breakdown
Enzalutamide Plus Androgen Deprivation Therapy: A Breakthrough in Prostate Cancer Treatment
10/22/2025, 10:44:24 AM
Overview of the EMBARK Trial
The phase 3 EMBARK trial (NCT02319837) has demonstrated that the combination of enzalutamide (Xtandi) and androgen deprivation therapy (ADT) significantly improves overall survival (OS) in patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) at high risk of biochemical recurrence. The trial's findings, presented at the 2025 European Society for Medical Oncology (ESMO) Congress and published in *The New England Journal of Medicine*, indicate a 40.3% reduction in the risk of death compared to ADT alone, establishing enzalutamide as a new standard of care for this patient population.
Key Findings and Patient Characteristics
The EMBARK trial enrolled 1,068 patients diagnosed with high-risk biochemically recurrent prostate cancer, characterized by a prostate-specific antigen (PSA) doubling time of less than nine months. Participants were randomly assigned to receive either enzalutamide plus leuprolide, leuprolide alone, or enzalutamide monotherapy. After eight years, the overall survival rate for the combination therapy was 78.9%, compared to 69.5% for leuprolide alone. Enzalutamide monotherapy did not show a statistically significant survival advantage over leuprolide alone, with a 17% reduction in the risk of death.
Implications for Treatment
Stephen Freedland, MD, co-principal investigator of the study, emphasized the significance of these findings, stating, “Hormone therapy, which is what we’ve been offering patients for 30 years, has not improved survival and neither has anything else. That makes these findings a real game changer.” The results are expected to strengthen the National Comprehensive Cancer Network's treatment guidelines, further solidifying enzalutamide plus ADT as the preferred regimen for high-risk patients.
Safety Profile and Adverse Effects
The safety profile of enzalutamide in the EMBARK trial was consistent with previous studies, with no new safety signals identified during the extended follow-up period. Common adverse events included fatigue, hot flashes, and musculoskeletal events. Serious adverse events related to the study drug occurred in 8.5% of the combination group, 7.6% in the enzalutamide monotherapy group, and 2.5% in the leuprolide-only group.
Criticism and Future Directions
While the results are promising, some experts highlight the need for ongoing research to optimize treatment strategies and minimize adverse effects. Freedland noted the potential of metastasis-directed therapy and the importance of exploring treatment suspension strategies to prolong the time off therapy while maintaining cancer benefits. Future studies will also investigate the effectiveness of enzalutamide monotherapy for patients concerned about preserving sexual health.
Verbatim Quotes
- “This marks the eighth publication of XTANDI data in The New England Journal of Medicine, further demonstrating XTANDI’s profound impact on clinical outcomes in men with certain types of advanced prostate cancer,” — Shontelle Dodson, Executive Vice President, Head of Medical Affairs, Astellas.
- “These important findings identify a treatment that prolongs survival in men with aggressive prostate cancer,” — Hyung Kim, MD, Chair of the Department of Urology at Cedars-Sinai.
The EMBARK trial's results represent a significant advancement in the management of high-risk nmCSPC, offering hope for improved outcomes in a patient population previously facing limited treatment options.
